The reaction to this compounding ban was like a Rorschach test for peoples feelings on how the government and the pharmaceutical industry serve the public good
Gralczyk-Bikowska A, Szmajda-Krygier D, Kozowska E
As of February 2026 , BPC-157 returned to Category 1 compounding status meaning licensed 503A and 503B compounding pharmacies can legally prepare it under physician prescription
For pain management, Thymosin Alpha-1 proves valuable in autoimmune-driven inflammation, chronic fatigue syndromes, and conditions where immune dysregulation contributes to tissue damage
Animal studies examining cartilage integrity have noted potential improvements in matrix composition and joint flexibility during recovery periods, making it a research candidate in post-injury musculoskeletal models
Brush-border peptidases then attack di- and tripeptides further